PhD Scientific Days 2022

Theoretical Medicine (Poster discussion will take place on the terrace of the room during the Coffee Break)

Efficacy and Safety Properties of Doxorubicin Delivered Using Thermo-Sensitive Liposomal Local Delivery Enhanced by Modulated Electro-Hyperthermia in a 4T1 Mouse Model

Előadó neve

Aloss, Kenan, MSc

Előadó munkahelye

Translational Medicine Institute

Előadó telefonszáma

+36302411221

Előadó e-mail címe

kenan.aless@hotmail.com

Az előadás címe

Efficacy and Safety Properties of Doxorubicin Delivered Using Thermo-Sensitive Liposomal Local Delivery Enhanced by Modulated Electro-Hyperthermia in a 4T1 Mouse Model

Szerző(k) neve és munkahelye

First Author: Kenan Aloss1
Second Authors: Csaba András Schvarcz1, Pedro Viana1 , Nino Guinasvilli1, Mahak Bokhari Zahra1, Zoltán Benyó1, Péter Hamar1
1. Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Theoretical Medicine (Poster discussion will take place on the terrace of the room during the Coffee Break)

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: Modulated electro-hyperthermia (mEHT) is an advanced option in the hyperthermia field, applying 13.56 Radiofrequency electromagnetic current to induce tumor-specific damage. Lyso-thermosensitive Liposomal Doxorubicin (LTLD) offers a promising approach to improve efficacy and reduce systematic toxicity of DOX.
Aims: check the efficacy and toxicity of LTLD+ mEHT combination

Methods: Triple-negative breast cancer cell line (4T1), was orthotopically injected into Balb/C mice and treated with LTLD (ThermoDox (Ceslion)). Tumor growth inhibition was followed and Dox concentration in the tumors was measured by spectrophotometry. Body weight, cardiac function and hematology were evaluated.
Results:
LTLD+ mEHT combination was significantly the most effective in tumor growth inhibition compared to DOX+ mEHT as demonstrated by both tumor volume and tumor weight reduction (tumor weight, LTLD+mEHT: 113.3±46.71mg vs DOX+mEHT: 170±51.43mg) (P=0.05). Moreover, the highest tumor destruction ratio (TDR) was observed in (LTLD+mEHT) group on HE stained samples (LTLD+mEHT:73.5±18.49%, DOX+mEHT: 61±15.38%, mEHT: 46.13±18.8%, DOX: 36.56±12.32%, sham:43.63±14.23%). Body weight loss was the strongest in the DOX+mEHT treated mice. LTLD reduced body weight loss significantly (LTLD+mEHT: 14.55± 4.66% vs DOX+ mEHT: 20.01± 3.65%) (P=0.02).
Conclusion:
mEHT can be an effective approach to deliver DOX-encapsulated in LTLD into TNBC tumors with a better safety profile.

Funding: EFOP-3.6.3-VEKOP-16-2017-00009

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Péter Hamar

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6828

Start

09:45

End

10:00

Authors (legacy)

First Author: Kenan Aloss1
Second Authors: Csaba András Schvarcz1, Pedro Viana1 , Nino Guinasvilli1, Mahak Bokhari Zahra1, Zoltán Benyó1, Péter Hamar1
1. Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary